Imprimis Pharmaceuticals Company Profile (NASDAQ:IMMY)

About Imprimis Pharmaceuticals (NASDAQ:IMMY)

Imprimis Pharmaceuticals logoImprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:IMMY
  • CUSIP: N/A
  • Web: www.imprimispharma.com
Capitalization:
  • Market Cap: $74.04 million
  • Outstanding Shares: 18,627,000
Average Prices:
  • 50 Day Moving Avg: $4.00
  • 200 Day Moving Avg: $2.89
  • 52 Week Range: $1.65 - $4.69
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.39
  • P/E Growth: -0.280
Sales & Book Value:
  • Annual Revenue: $21.66 million
  • Price / Sales: 3.17
  • Book Value: $0.27 per share
  • Price / Book: 13.67
Profitability:
  • EBIDTA: ($14,270,000.00)
  • Net Margins: -102.59%
  • Return on Equity: -457.59%
  • Return on Assets: -87.29%
Debt:
  • Debt-to-Equity Ratio: 3.94%
  • Current Ratio: 1.55%
  • Quick Ratio: 1.22%
Misc:
  • Average Volume: 263,478 shs.
  • Beta: 0.61
  • Short Ratio: 4.88
 

Frequently Asked Questions for Imprimis Pharmaceuticals (NASDAQ:IMMY)

What is Imprimis Pharmaceuticals' stock symbol?

Imprimis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMMY."

How were Imprimis Pharmaceuticals' earnings last quarter?

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) released its earnings results on Wednesday, May, 10th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.07. The business earned $6.10 million during the quarter, compared to analyst estimates of $6.50 million. Imprimis Pharmaceuticals had a negative net margin of 102.59% and a negative return on equity of 457.59%. View Imprimis Pharmaceuticals' Earnings History.

Where is Imprimis Pharmaceuticals' stock going? Where will Imprimis Pharmaceuticals' stock price be in 2017?

3 brokers have issued twelve-month target prices for Imprimis Pharmaceuticals' stock. Their predictions range from $5.00 to $5.00. On average, they anticipate Imprimis Pharmaceuticals' share price to reach $5.00 in the next twelve months. View Analyst Ratings for Imprimis Pharmaceuticals.

Who are some of Imprimis Pharmaceuticals' key competitors?

Who owns Imprimis Pharmaceuticals stock?

Imprimis Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Marathon Asset Management LP (3.95%), Granite Investment Partners LLC (1.60%), Vanguard Group Inc. (1.36%), Berson & Corrado Investment Advisors LLC (0.64%), Apollo Management Holdings L.P. (0.54%) and Bard Associates Inc. (0.33%). Company insiders that own Imprimis Pharmaceuticals stock include Andrew R Boll, Mark L Baum, Opaleye Management Inc and Richard L Md Lindstrom. View Institutional Ownership Trends for Imprimis Pharmaceuticals.

Who sold Imprimis Pharmaceuticals stock? Who is selling Imprimis Pharmaceuticals stock?

Imprimis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Marathon Asset Management LP and Bard Associates Inc.. View Insider Buying and Selling for Imprimis Pharmaceuticals.

Who bought Imprimis Pharmaceuticals stock? Who is buying Imprimis Pharmaceuticals stock?

Imprimis Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, Apollo Management Holdings L.P., Vanguard Group Inc., KCG Holdings Inc., Wealthsource Partners LLC, Berson & Corrado Investment Advisors LLC and Geode Capital Management LLC. Company insiders that have bought Imprimis Pharmaceuticals stock in the last two years include Andrew R Boll, Mark L Baum, Opaleye Management Inc and Richard L Md Lindstrom. View Insider Buying and Selling for Imprimis Pharmaceuticals.

How do I buy Imprimis Pharmaceuticals stock?

Shares of Imprimis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Imprimis Pharmaceuticals stock cost?

One share of Imprimis Pharmaceuticals stock can currently be purchased for approximately $3.69.

Analyst Ratings

Consensus Ratings for Imprimis Pharmaceuticals (NASDAQ:IMMY) (?)
Ratings Breakdown: 1 Sell Rating, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $5.00 (35.50% upside)

Analysts' Ratings History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/16/2017ValuEngineDowngradeSell -> Strong SellLowView Rating Details
3/22/2017Rodman & RenshawReiterated RatingBuy$5.00HighView Rating Details
11/28/2016HC WainwrightInitiated CoverageBuy$5.00N/AView Rating Details
7/23/2015Sterne Agee CRTInitiated CoverageBuy$10.00N/AView Rating Details
(Data available from 5/22/2015 forward)

Earnings

Earnings History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Earnings by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Earnings History by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.19)($0.26)$6.50 million$6.10 millionViewN/AView Earnings Details
3/21/2017Q4 2016($0.28)($0.44)$5.50 million$5.79 millionViewN/AView Earnings Details
11/14/2016Q316($0.24)($0.29)$2.70 million$4.90 millionViewN/AView Earnings Details
8/15/2016Q216($0.35)$4.53 million$4.90 millionViewListenView Earnings Details
5/12/2016Q116($0.27)($0.43)$3.24 million$4.40 millionViewListenView Earnings Details
3/23/2016Q415($0.26)($0.53)$3.52 million$3.50 millionViewListenView Earnings Details
8/12/2015Q215($0.33)($0.39)$2.13 million$2.00 millionViewListenView Earnings Details
5/13/2015Q115($0.25)($0.33)$1.55 million$16.00 millionViewN/AView Earnings Details
3/12/2015Q414($0.25)($0.30)$0.68 million$0.55 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Current Year EPS Consensus Estimate: $-0.86 EPS
Next Year EPS Consensus Estimate: $-0.44 EPS

Dividends

Dividend History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Insider Ownership Percentage: 14.59%
Institutional Ownership Percentage: 25.14%
Insider Trades by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Institutional Ownership by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Insider Trades by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/19/2016Andrew R BollCFOBuy39,000$1.79$69,810.00View SEC Filing  
12/19/2016Mark L BaumCEOBuy156,000$1.79$279,240.00View SEC Filing  
12/19/2016Richard L Md LindstromDirectorBuy100,000$1.79$179,000.00View SEC Filing  
3/11/2016Opaleye Management Inc.Major ShareholderBuy45,000$3.65$164,250.00View SEC Filing  
6/30/2015Opaleye Management Inc.Major ShareholderBuy35,000$7.90$276,500.00View SEC Filing  
5/19/2015Donald Paul MiloniMajor ShareholderSell410,000$8.00$3,280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Latest Headlines for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Source:
DateHeadline
americanbankingnews.com logoImprimis Pharmaceuticals Inc (IMMY) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - May 16 at 3:58 PM
americanbankingnews.com logoImprimis Pharmaceuticals Inc (IMMY) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS
www.americanbankingnews.com - May 11 at 7:36 PM
finance.yahoo.com logoImprimis Pharmaceuticals Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 6:22 PM
finance.yahoo.com logoImprimis reports 1Q loss
finance.yahoo.com - May 10 at 6:22 PM
finance.yahoo.com logoInvestor Network: Imprimis Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 10 at 1:20 PM
finance.yahoo.com logoInvestor Network Invites You to the Imprimis Pharmaceuticals First Quarter 2017 Earnings Conference Call and Webcast Live on Wednesday, May 10, 2017
finance.yahoo.com - May 9 at 5:41 PM
finance.yahoo.com logoImprimis Pharmaceuticals to Launch its Simple Drops™ Combination Glaucoma Drops at Leading Cataract & Refractive Surgery Medical Meeting
finance.yahoo.com - May 4 at 6:03 PM
americanbankingnews.com logoImprimis Pharmaceuticals (IMMY) Receives Daily News Sentiment Rating of 0.31
www.americanbankingnews.com - May 2 at 10:30 PM
finance.yahoo.com logoImprimis Pharmaceuticals and SightLife Surgical Sign Agreement for National Launch of Serum Tears™
finance.yahoo.com - May 2 at 10:26 AM
finance.yahoo.com logoImprimis Pharmaceuticals to Host its First Quarter 2017 Financial Report Conference Call and Webcast …
finance.yahoo.com - May 1 at 1:20 PM
finance.yahoo.com logoImprimis Pharmaceuticals to Host its First Quarter 2017 Financial Report Conference Call and Webcast on May 10, 2017 at 4:15 p.m. EDT
finance.yahoo.com - May 1 at 1:20 PM
americanbankingnews.com logoImprimis Pharmaceuticals (IMMY) Receives Coverage Optimism Rating of 0.35
www.americanbankingnews.com - April 28 at 6:24 PM
americanbankingnews.com logoImprimis Pharmaceuticals (IMMY) Earning Favorable News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 21 at 10:36 PM
finance.yahoo.com logoCan The Uptrend Continue for Imprimis Pharmaceuticals (IMMY)?
finance.yahoo.com - April 21 at 10:43 AM
americanbankingnews.com logoImprimis Pharmaceuticals (IMMY) Earns Daily News Impact Score of 0.16
www.americanbankingnews.com - April 18 at 8:50 PM
finance.yahoo.com logoImprimis Pharmaceuticals and Precision Lens Sign Agreement to Expand Imprimis' Ophthalmic Portfolio Market Opportunity in the U.S. Midwest
finance.yahoo.com - April 18 at 11:05 AM
americanbankingnews.com logoImprimis Pharmaceuticals (IMMY) Getting Somewhat Positive News Coverage, Study Finds
www.americanbankingnews.com - April 15 at 11:45 AM
americanbankingnews.com logoImprimis Pharmaceuticals Inc (IMMY) Sees Significant Increase in Short Interest
www.americanbankingnews.com - April 11 at 7:12 AM
finance.yahoo.com logoETFs with exposure to Imprimis Pharmaceuticals, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 5:46 PM
streetinsider.com logoImprimis Pharma (IMMY) Buys Exclusive License to Patented Ophthalmic Formulation for Dry Eye Disease
www.streetinsider.com - April 7 at 10:25 AM
finance.yahoo.com logoImprimis Pharmaceuticals Acquires Exclusive License to Patented Ophthalmic Formulation for Dry Eye Disease
finance.yahoo.com - April 7 at 10:25 AM
americanbankingnews.com logoAnalysts Expect Imprimis Pharmaceuticals Inc (IMMY) to Post ($0.19) EPS
www.americanbankingnews.com - April 4 at 12:01 AM
finance.yahoo.com logoCan The Uptrend Continue for Teck Resources (IMMY)?
finance.yahoo.com - March 31 at 5:56 PM
finance.yahoo.com logoImprimis Pharmaceuticals (IMMY) Jumps: Stock Rises 10%
finance.yahoo.com - March 27 at 10:59 AM
finance.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Financials
finance.yahoo.com - March 25 at 5:38 PM
americanbankingnews.com logoImprimis Pharmaceuticals Inc (IMMY) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - March 24 at 12:28 PM
americanbankingnews.com logoRodman & Renshaw Reiterates "Buy" Rating for Imprimis Pharmaceuticals Inc (IMMY)
www.americanbankingnews.com - March 22 at 8:34 PM
seekingalpha.com logoImprimis Pharmaceuticals' (IMMY) CEO Mark Baum on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 22 at 6:04 PM
finance.yahoo.com logoMore Than 100% Upside Seen In Imprimis After Q4 Results
finance.yahoo.com - March 22 at 6:04 PM
us.rd.yahoo.com logo8:01 am Imprimis Pharmaceuticals entered into agreements with two accredited investors for a registered direct placement of 1,312,000 shares of common stock at a price of $2.40 per share
us.rd.yahoo.com - March 22 at 9:56 AM
biz.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financia
biz.yahoo.com - March 22 at 9:56 AM
americanbankingnews.com logoImprimis Pharmaceuticals Inc (IMMY) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 22 at 9:17 AM
us.rd.yahoo.com logoImprimis Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial Results
us.rd.yahoo.com - March 21 at 5:53 PM
biz.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 21 at 5:53 PM
biz.yahoo.com logoQ4 2016 Imprimis Pharmaceuticals Inc Earnings Release - After Market Close
biz.yahoo.com - March 21 at 9:20 AM
finance.yahoo.com logoPeer-Reviewed Paper Demonstrates the Benefits of Dropless Cataract Surgery®
finance.yahoo.com - March 20 at 6:55 PM
finance.yahoo.com logoInvestor Network Invites You to the Imprimis Pharmaceuticals Fourth Quarter and Year End 2016 Earnings Conference Call and Webcast Live on Tuesday, March 21, 2017
finance.yahoo.com - March 20 at 6:55 PM
finance.yahoo.com logoImprimis Pharmaceuticals to Host its Fourth Quarter and Fiscal Year 2016 Financial Report Conference Call and Webcast on March 21, 2017 at 4:30 p.m. EDT
finance.yahoo.com - March 7 at 11:02 AM
biz.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisit
biz.yahoo.com - February 17 at 5:32 PM
finance.yahoo.com logoImprimis Pharmaceuticals Begins Dispensing from FDA-Registered 503B Outsourcing Facility
finance.yahoo.com - February 16 at 8:12 AM
biz.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct F
biz.yahoo.com - January 4 at 2:00 AM
biz.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of E
biz.yahoo.com - December 23 at 6:08 PM
finance.yahoo.com logoImprimis Pharmaceuticals Inc (IMMY) CEO Mark L Baum Bought $279,240 of Shares
finance.yahoo.com - December 21 at 6:45 PM
finance.yahoo.com logoImprimis Pharmaceuticals and FocusScript Partner to Exclusively Offer the Correct Compound™ Program
finance.yahoo.com - December 21 at 9:17 AM
streetinsider.com logoImprimis Pharma (IMMY) Reports $9.8M Private Placement of Common stock and Warrants
www.streetinsider.com - December 20 at 11:17 AM
finance.yahoo.com logoImprimis Pharmaceuticals Announces $9.8 Million Private Placement of Units
finance.yahoo.com - December 20 at 11:17 AM
finance.yahoo.com logo4:31 pm Imprimis Pharmaceuticals enters into a definitive securities purchase agreement with various accredited investors and certain members of Imprimis' Board of Directors and senior management to raise gross proceeds of approx. $9.8 mill
finance.yahoo.com - December 20 at 11:17 AM
finance.yahoo.com logoImprimis CEO Talks Phenomenal Quarter: 'Shocking' Statistics, Simplification And A Trifecta For Success
finance.yahoo.com - December 1 at 5:53 PM
finance.yahoo.com logoCoverage initiated on Imprimis Pharmaceuticals by Rodman & Renshaw
finance.yahoo.com - November 29 at 4:34 PM
finance.yahoo.com logoImprimis Pharmaceuticals Ranked 12 on Deloitte's 2016 Technology Fast 500™ List of Fastest Growing Companies in North America
finance.yahoo.com - November 17 at 8:53 AM

Social

Imprimis Pharmaceuticals (IMMY) Chart for Monday, May, 22, 2017

This page was last updated on 5/22/2017 by MarketBeat.com Staff